BioRestorative Therapies (BRTX) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	14-May-15
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1505497
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	BRTX
Entity Common Stock, Shares Outstanding		39,151,442

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current Assets:
Cash	$145,866	$91,798
Inventories	1,927	1,945
Prepaid expenses and other current assets	32,438	20,570
Total Current Assets	180,231	114,313
Property and equipment, net	537,155	493,856
Intangible assets, net	1,094,913	1,037,732
Security deposit	45,900	45,900
Total Assets	1,858,199	1,691,801
Current Liabilities:
Accounts payable	1,265,550	1,111,879
Accrued expenses and other current liabilities	1,884,559	1,466,506
Accrued interest	97,816	94,026
Current portion of notes payable, net of debt discount of $60,332 and $113,257 at March 31, 2015 and December 31, 2014, respectively	5,463,291	5,688,239
Deferred revenues	210,882	164,349
Total Current Liabilities	8,922,098	8,524,999
Accrued interest, non-current portion	23,520	5,195
Notes payable, non-current portion	307,873	50,000
Total Liabilities	9,253,491	8,580,194
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares; none issued and outstanding at March 31, 2015 and December 31, 2014	0	0
Common stock, $0.001 par value; Authorized, 200,000,000 shares; Issued 37,750,173 and 34,511,800 shares at March 31, 2015 and December 31, 2014, respectively; Outstanding 37,191,552 and 33,953,179 shares at March 31, 2015 and December 31, 2014, respectively	37,750	34,512
Additional paid-in capital	19,759,105	18,509,121
Accumulated deficit	-27,160,147	-25,400,026
Treasury stock, at cost, 558,621 shares at March 31, 2015 and December 31, 2014	-32,000	-32,000
Total Stockholders' Deficiency	-7,395,292	-6,888,393
Total Liabilities and Stockholders' Deficiency	$1,858,199	$1,691,801

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current portion of notes payable, debt discount	$60,332	$113,257
Preferred stock, par value	$0.01	$0.01
Preferred stock, Authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, Authorized	200,000,000	200,000,000
Common stock, Issued	37,750,173	34,511,800
Common stock, Outstanding	37,191,552	33,953,179
Treasury stock, at cost, shares	558,621	558,621

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenues	$184,902	$375
Cost of sales	76,432	60
Gross Profit	108,470	315
Operating Expenses
Marketing and promotion	44,937	31,794
Consulting	365,069	267,198
Research and development	406,856	493,741
General and administrative	917,574	636,000
Total Operating Expenses	1,734,436	1,428,733
Loss From Operations	-1,625,966	-1,428,418
Other (Expense) Income
Interest expense	-64,640	-73,131
Amortization of debt discount	-69,515	-98,505
Loss on extinguishment of notes payable, net	0	-49,094
Warrant modification expense	0	-30,128
Gain on settlement of payables	0	9,600
Total Other Expense	-134,155	-241,258
Net Loss	($1,760,121)	($1,669,676)
Net Loss Per Share - Basic and Diluted	($0.05)	($0.08)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	35,107,957	20,237,689

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficiency) (USD $)	Total	Cash	Common Stock and Warrants	Common Stock	Additional paid-in capital	Additional paid-in capital	Accumulated deficit	Accumulated deficit	Treasury Stock	Treasury Stock
			Cash			Cash		Cash		Cash
Beginning Balance at Dec. 31, 2014	($6,888,393)			$34,512	$18,509,121		($25,400,026)		($32,000)
Beginning Balance (in shares) at Dec. 31, 2014				34,511,800					-558,621
Shares and warrants issued for cash		801,000	2,703			798,297		0		0
Shares and warrants issued for cash (in shares)			2,703,333							0
Conversion of notes payable and accrued interest into common stock	55,984			222	55,762		0		0
Conversion of notes payable and accrued interest into common stock (in shares)				222,245					0
Shares issued in satisfaction of accrued services	8,481			19	8,462
Shares issued in satisfaction of accrued services (in shares)				18,847
Warrant modification in connection with extension of notes payable	5,900			0	5,900		0		0
Beneficial conversion features related to convertible notes payable	10,690			0	10,690		0		0
Stock-based compensation: - common stock	76,647			294	76,353		0		0
Stock-based compensation: - common stock (in shares)				293,948					0
Stock-based compensation: - options	294,520			0	294,520		0		0
Net loss	-1,760,121			0	0		-1,760,121		0
Shares issued in satisfaction of accrued consulting services							0		0
Shares issued in satisfaction of accrued consulting services (in shares)									0
Ending Balance at Mar. 31, 2015	($7,395,292)			$37,750	$19,759,105		($27,160,147)		($32,000)
Ending Balance (in shares) at Mar. 31, 2015				37,750,173					-558,621

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash Flows From Operating Activities
Net loss	($1,760,121)	($1,669,676)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	69,515	98,505
Depreciation and amortization	39,613	25,517
Loss on sale of property and equipment	0	1,009
Stock-based compensation	371,167	373,499
Loss on extinguishment of note and payables, net	0	49,094
Gain on settlement of payables	0	-9,600
Warrant modification expense	0	30,128
Changes in operating assets and liabilities:
Inventories	18	61
Prepaid expenses and other current assets	-11,868	11,686
Accounts payable	80,534	-59,380
Accrued interest, expenses and other current liabilities	489,831	192,429
Deferred revenues	46,533	150,000
Total Adjustments	1,085,343	862,948
Net Cash Used In Operating Activities	-674,778	-806,728
Cash Flows From Investing Activities
Purchases of property and equipment	-92,169	0
Proceeds from sale of property and equipment	0	980
License maintenance costs	-75,000	0
Net Cash (Used In) Provided By Investing Activities	-167,169	980
Cash Flows From Financing Activities
Proceeds from notes payable	30,000	140,000
Repayments of notes payable	0	-25,000
Advances from officer	125,070	0
Repayment of advances from officer	-60,055	-24,990
Proceeds from exercise of warrants	0	80,000
Sales of common stock and warrants for cash	801,000	545,000
Net Cash Provided by Financing Activities	896,015	715,010
Net Increase (Decrease) In Cash	54,068	-90,738
Cash - Beginning	91,798	201,098
Cash - Ending	145,866	110,360
Cash paid during the period for:
Interest	36,540	16,804
Non-cash investing and financing activities:
Conversion of notes payable and accrued interest into common stock	55,984	0
Shares and warrants issued in exchange for notes payable and accrued interest	0	343,026
Beneficial conversion features set up as debt discount	10,690	0
Change in accrued liabilities associated with Accrued purchases of property and equipment	64,276	0
Payments for previously accrued property and equipment	-91,352	0
Warrant modification in connection with extension of notes payable
Non-cash investing and financing activities:
Shares issued	5,900	0
Shares issued in satisfaction of accrued consulting services
Non-cash investing and financing activities:
Shares issued	$8,481	$0

Business_Organization_Nature_o

Business Organization, Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization, Nature of Operations and Basis of Presentation
	BioRestorative Therapies, Inc. (and including its subsidiaries, “BRT” or the “Company”) develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells designed for personal medical applications. BRT’s website is at www.biorestorative.com. BRT is currently pursuing a Disc/Spine Program. Its lead cell therapy candidate, brtxDISC™ (Disc Implanted Stem Cells), is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. The product is intended to be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRT is also engaging in research efforts with respect to a platform technology utilizing brown adipose (fat) for therapeutic purposes and has labeled this initiative its ThermoStem® Program. It is a pre-clinical cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue and is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. BRT has developed an ingredient derived from human adult stem cells, which can be used by third party companies in the development of their own skin care products. The ingredient was developed pursuant to BRT’s brtx-C Cosmetic Program. BRT’s Stem Pearls® brand offers plant stem cell-based cosmetic skincare products that are available for purchase online at www.stempearls.com.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of March 31, 2015 and for the three months ended March 31, 2015 and 2014. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full year ending December 31, 2015 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2014 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on March 31, 2015.
	Effective January 1, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion, dated December 22, 2014 (the “Plan of Conversion”). Pursuant to the Plan of Conversion, the Company also adopted new bylaws, which became effective on January 1, 2015.

Going_Concern_and_Managements_

Going Concern and Management's Plans	3 Months Ended
	Mar. 31, 2015
Development Stage Enterprises [Abstract]
Going Concern and Management Plans	Note 2 – Going Concern and Management’s Plans
	As of March 31, 2015, the Company had a working capital deficiency and a stockholders’ deficiency of $8,741,867 and $7,395,292, respectively. During the three months ended March 31, 2015 and 2014, the Company incurred net losses of $1,760,121 and $1,669,676, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	Despite recent revenue generated from specific research and development contracts, the Company's primary source of operating funds since inception has been, and will continue to be for the foreseeable future, equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis and, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.
	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.
	Subsequent to March 31, 2015, (a) the Company has raised an aggregate of $200,000 and $100,000 through equity financing and debt financing, respectively, and (b) $307,873 and $26,501 of debt and accrued interest, respectively, has been exchanged for or converted into common stock. As a result, the Company expects to be able to fund its operations through June 2015. While there can be no assurance that it will be successful, the Company is in active negotiations to raise additional capital. See Note 8 – Subsequent Events for additional details.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies
	Principles of Consolidation
	The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s equity securities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
	Concentrations and Credit Risk
	As of March 31, 2015, 76% of the face value of the Company’s outstanding notes payable were sourced from a single entity (the “Bermuda Lender”). As of the date of filing, the maturity date associated with these notes was June 30, 2015. See Note 5 – Notes Payable and Note 8 – Subsequent Events – Note Payable for additional discussion of the Bermuda Lender.
	Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three months ended March 31, 2015. See Revenue Recognition – Research and Development Agreements below.
	Revenue Recognition
	Research and Development Agreements
	The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables.
	During the three months ended March 31, 2015, in connection with a March 19, 2014 research and development agreement with a Japanese pharmaceutical company, the Company received $50,000 upon achievement of a specified deliverable (milestone method). Through March 31, 2015, $200,000 had been received under the agreement and recognized as revenue. On February 11, 2015, the term of the agreement was extended by three months to June 19, 2015.
	During the three months ended March 31, 2015, in connection with a March 24, 2014 research and development agreement with a U.S. pharmaceutical company, the Company received the third and fourth of four quarterly payments in the aggregate amount of $177,234. Through March 31, 2015, $605,359 had been received and $210,882 was recorded as deferred revenues on the condensed consolidated balance sheet.
	During the three months ended March 31, 2015, the Company recognized revenue related to research and development agreements of $180,702. The Company did not recognize any revenue related to research and development agreements during the three months ended March 31, 2014.
	Other
	The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.
	For the three months ended March 31, 2015 and 2014, the Company recognized revenue related to sales of Stem Pearls® skincare products of $200 and $375, respectively. In connection with its January 27, 2012 sublicense agreement with a stem cell treatment company, for the three months ended March 31, 2015 and 2014, the Company recognized royalty revenue of $4,000 and $0, respectively.
	Net Loss Per Common Share
	Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes.
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		March 31,
		2015		2014
	Options		16,184,000		7,783,000
	Warrants		9,099,516		5,325,751
	Convertible instruments		678,806		1,519,015
	Total potentially dilutive shares		25,962,322		14,627,766
	Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTCQB. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
	Subsequent Events
	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2015
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities
	Accrued expenses and other current liabilities are comprised of the following:
		March 31,		December 31,
		2015		2014
		(unaudited)
	Credit card payable	$	3,971	$	4,739
	Accrued payroll and payroll taxes		777,757		679,277
	Accrued purchases of property and equipment		74,587		174,801
	Accrued research and development expenses		316,175		292,395
	Accrued general and administrative expenses		679,069		315,294
	Deferred rent		33,000		-
	Total	$	1,884,559	$	1,466,506
	During the three months ended March 31, 2015, the Company received an aggregate of $125,070 in non-interest bearing advances from an officer and made aggregate repayments of $60,055, such that the Company has $65,015 remaining liability with regard to these advances as of March 31, 2015. During the three months ended March 31, 2014, the Company made aggregate repayments to a director and a family member of an officer of $24,990, such that the Company had no remaining liability at March 31, 2014.

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2015
Notes Payable [Abstract]
Notes Payable	Note 5 – Notes Payable
	A summary of the notes payable activity during the three months ended March 31, 2015 is presented below:
			Bermuda		Convertible			Other		Debt
			Lender		Notes			Notes		Discount		Total
	Outstanding, December 31, 2014		$	4,410,937	$	175,000		$	1,265,559	$	-113,257	$	5,738,239
	Issuance			-		30,000			-		-		30,000
	Conversion to equity			-		-50,000			-		-		-50,000
	Recognition of debt discount			-		-			-		-16,590		-16,590
	Amortization of debt discount			-		-			-		69,515		69,515
	Outstanding, March 31, 2015		$	4,410,937	$	155,000	[1]	$	1,265,559	$	-60,332	$	5,771,164
		[1]	As of March 31, 2015, convertible notes with an aggregate principal balance of $155,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.
	Bermuda Lender
	As of March 31, 2015, the Bermuda Lender is a related party as a result of the size of its ownership interest in the Company's common stock.
	See Note 3 – Summary of Significant Accounting Policies – Concentrations and Credit Risk and Note 8 – Subsequent Events – Note Payable for additional discussion of the Bermuda Lender.
	Convertible Notes
	On January 25, 2015, the Company issued a six-month convertible note with a principal amount of $30,000 which bears interest at a rate of 12% per annum payable upon maturity. The convertible note is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at the greater of (a) 55% of the fair value of the Company’s stock or (b) $0.10 per share.
	On February 17, 2015, the Company elected to convert a convertible note with a principal balance of $50,000 and accrued interest of $5,984 into 222,245 shares of common stock at a conversion price of $0.25 per share.
	During the three months ended March 31, 2015, the contingently adjustable conversion ratio associated with a certain convertible note was resolved. The Company estimated the intrinsic value of the embedded conversion option based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the three months ended March 31, 2015, the Company recognized $10,690 of intrinsic value related to the beneficial conversion feature as debt discount which was immediately amortized.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies
	Operating Lease
	Rent expense amounted to approximately $35,000 and $11,000 during the three months ended March 31, 2015 and 2014, respectively, which is reflected in general and administrative expenses in the condensed consolidated statements of operations.
	Litigations, Claims and Assessments
	In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business.
	In November 2013, an action was commenced against the Company in the Circuit Court of Palm Beach County, Florida by an alleged former consultant. The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009. Pursuant to the action, the plaintiff was seeking to recover an unspecified amount of damages as well as the repayment of the alleged loan with interest, reimbursement for certain out-of-pocket fees and expenses, two weeks vacation pay per year, and the issuance of shares of the Company’s common stock (or alternatively the market value of such securities). On April 27, 2015, the Company and the plaintiff entered into a settlement agreement for an amount which has been accrued as of March 31, 2015.
	The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.
	Employment Agreements
	On February 9, 2015, the Company hired a President for its Disc/Spine Division (“Division President”) pursuant to an at-will employment agreement which entitles him to a specified salary and a discretionary bonus. In the event the Company terminates the Division President without cause, the Division President is entitled to cash severance payments of $150,000 paid over nine months. As additional compensation, the Company granted the Division President a ten-year option to purchase 500,000 shares of common stock at an exercise price of $0.46 per share, pursuant to the Plan. The shares vest over three years on the grant date anniversaries. The grant date value of $200,400 will be recognized proportionate to the vesting period.
	On March 9, 2015, the Company and its Chief Executive Officer (“CEO”) agreed to extend the term of his employment agreement to December 31, 2017. Pursuant to the employment agreement, the CEO is entitled to receive a salary of $400,000 per annum. The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Company’s Compensation Committee, are satisfied. Pursuant to the employment agreement, in the event that the CEO’s employment is terminated by the Company without cause, or the CEO terminates his employment for “good reason” (each as defined in the employment agreement), the CEO would be entitled to receive severance in an amount equal to his then annual base salary and certain benefits, plus $100,000 (in lieu of bonus). In addition, pursuant to the employment agreement, the CEO would also be entitled to receive such severance in the event that the term of his employment agreement is not extended beyond December 31, 2017 and, within three months of such expiration date, his employment is terminated by the Company without “cause” or the CEO terminates his employment for any reason. Further, in the event that the CEO’s employment is terminated by the Company without cause, or the CEO terminates his employment for “good reason”, following a “change in control” (as defined in the employment agreement), the CEO would be entitled to receive severance in an amount equal to one and one-half times his then annual base salary and certain benefits, plus $300,000 (in lieu of bonus).
	On March 9, 2015, the Company agreed to amend the at-will employment agreement with its Vice President of Research and Development (“VP of R&D”). Pursuant to the employment agreement, as amended, in the event that the VP of R&D’s employment with the Company is terminated without cause, the VP of R&D would currently be entitled to receive a cash severance payment equal to one-half of his base annual salary (such one-half amount currently $125,000).

Stockholders_Deficiency

Stockholders' Deficiency	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 7 – Stockholders’ Deficiency
	Authorized Capital
	On December 19, 2014, effective January 1, 2015, the Company’s shareholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware and in connection therewith (i) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000; and (ii) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of preferred stock authorized to be issued by the Company from 1,000,000 to 5,000,000.
	Warrant and Option Valuation
	The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate ranging from 0% to 5% for options granted during the three months ended March 31, 2015 and 2014. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee and director option grants. Since the Company’s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.
	Common Stock and Warrant Offerings
	During the three months ended March 31, 2015, the Company issued an aggregate of 2,703,333 shares of common stock at prices ranging from $0.25 to $0.30 per share to investors for aggregate gross proceeds of $801,000. In connection with the purchases, the Company issued warrants to purchase an aggregate of 850,833 shares of common stock at exercise prices ranging from $0.40 to $0.75 per share of common stock. The warrants have a term of five years. The warrants had an aggregate issuance date value of $138,383.
	Stock Warrants
	In applying the Black-Scholes option pricing model to warrants granted/issued, the Company used the following assumptions:
			For The Three Months Ended
			March 31,
			2015			2014
	Risk free interest rate			1.22% - 1.61	%		0.39% - 2.20	%
	Expected term (years)			5			1.96 - 5.00
	Expected volatility			122	%		121	%
	Expected dividends			0	%		0	%
	The weighted average estimated fair value of the warrants granted/issued during the three months ended March 31, 2015 and 2014 was approximately $0.16 and $0.22 per share, respectively.
	See Note 7 – Stockholders’ Deficiency – Common Stock and Warrant Offerings for details associated with the issuance of warrants in connection with common stock and warrant offerings.
	The Company recorded stock–based compensation expense of $0 and $53,726 during the three months ended March 31, 2015 and 2014, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the condensed consolidated statements of operations. As of March 31, 2015, there was no unrecognized stock-based compensation expense related to stock warrants.
	A summary of the warrant activity during the three months ended March 31, 2015 is presented below:
									Weighted
						Weighted			Average
						Average			Remaining			Aggregate
			Number of			Exercise			Life			Intrinsic
			Warrants			Price			In Years			Value
	Outstanding, December 31, 2014			8,248,683		$	0.9
	Granted			850,833			0.68
	Exercised			-			-
	Forfeited			-			-
	Outstanding, March 31, 2015			9,099,516		$	0.88			3.1		$	-
	Exercisable, March 31, 2015			8,399,516		$	0.83			3.2		$	-
	The following table presents information related to stock warrants at March 31, 2015:
	Warrants Outstanding							Warrants Exercisable
								Weighted
						Outstanding		Average			Exercisable
	Exercise				Number of			Remaining Life			Number of
	Price				Warrants			In Years			Warrants
	$	0.3				650,000			4.2			650,000
		0.4				250,000			4.7			250,000
		0.5				677,100			4.7			677,100
		0.53				380,000			3.1			380,000
		0.58				50,000			4.5			50,000
		0.75				4,669,222			2.9			4,669,222
		0.94				50,000			4.5			50,000
		1				550,000			4.2			550,000
		1.5				862,800			2.2			862,800
		1.75				20,000			2			20,000
		2				123,530			3.6			123,530
		2.5				20,000			2.3			20,000
		3				36,864			3.1			36,864
		4				60,000			2.5			60,000
		Variable	[1]			700,000			-			-
						9,099,516			3.2			8,399,516
		[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur as of March 31, 2015.
	Stock Options
	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:
			For the Three Months Ended
			March 31,
			2015			2014
	Risk free interest rate			1.33% - 1.64	%		1.5	%
	Expected term (years)			5.00 - 6.00			5.00 - 5.50
	Expected volatility			122	%		121	%
	Expected dividends			0	%		0	%
	The weighted average estimated fair value of the stock options granted during the three months ended March 31, 2015 and 2014 was approximately $0.40 and $0.23 per share, respectively.
See Note 6 – Commitments and Contingencies – Employment Agreements for details associated with the grant of stock options in connection with employment agreements.
On January 23, 2015, the Company granted five-year options to consultants to purchase an aggregate of 100,000 shares of common stock at an exercise price of $0.47 per share, pursuant to the Plan. The shares vest as follows: (i) 75,000 shares vest ratably over three months from the date of grant, (ii) 12,500 shares vest immediately and (iii) 12,500 shares vest on the anniversary of the date of grant. The aggregate grant date value of $39,200 will be recognized proportionate to the vesting period.
The following table presents information related to stock option expense:
											Weighted
											Average
		For the Three Months Ended						Unrecognized at			Amortization
		March 31,						March 31,			Period
		2015			2014			2015			(Years)
Consulting		$	96,803		$	100,613		$	585,273			2.3
Research and development			128,432			121,390			755,231	[1]		2.4
General and administrative			69,285			83,699			862,726			2.4
		$	294,520		$	305,702		$	2,203,230			2.4
	[1]	Includes $331,341 of expense that is subject to non-employee mark-to-market adjustments.
A summary of the option activity during the three months ended March 31, 2015 is presented below:
								Weighted
					Weighted			Average
					Average			Remaining			Aggregate
		Number of			Exercise			Life			Intrinsic
		Options			Price			In Years			Value
Outstanding, December 31, 2014			15,584,000		$	0.61
Granted			600,000			0.46
Exercised			-			-
Forfeited			-			-
Outstanding, March 31, 2015			16,184,000		$	0.6			8.3		$	587,850
Exercisable, March 31, 2015			7,196,502		$	0.88			7.5		$	28,850
The following table presents information related to stock options at March 31, 2015:
Options Outstanding						Options Exercisable
						Weighted
			Outstanding			Average			Exercisable
Exercise			Number of			Remaining Life			Number of
Price			Options			In Years			Options
$	0.285			900,000			9.2			200,000
	0.32			500,000			-			-
	0.33			6,125,000			4.5			75,000
	0.34			250,000			-			-
	0.39			60,000			4.2			60,000
	0.46			500,000			-			-
	0.47			100,000			4.8			87,500
	0.5			345,000			4.6			345,000
	0.53			40,000			8.9			40,000
	0.6			980,000			8.5			980,000
	0.65			2,675,000			8.6			1,850,002
	1			131,000			7.7			131,000
	1.05			2,270,000			6.9			2,270,000
	1.1			5,000			2.2			5,000
	1.2			10,000			1.2			10,000
	1.25			43,000			1.6			43,000
	1.4			350,000			4.3			200,000
	1.5			900,000			7.7			900,000
				16,184,000			7.5			7,196,502
Compensatory Common Stock Issuances
During the three months ended March 31, 2015, the Company issued an aggregate of 312,795 shares of common stock valued at $85,128 to consultants pursuant to consulting agreements.
The following table presents information related to compensatory common stock expense and does not include 18,847 shares valued at $8,481 which were issued in satisfaction of accrued professional services:
		For the Three Months Ended						Unrecognized at
		March 31,						March 31,
		2015			2014			2015
Consulting		$	67,800		$	10,000		$	-
Research and development			8,847			4,071			-
		$	76,647		$	14,071		$	-
A summary of compensatory common stock issuances activity during the three months ended March 31, 2015 is presented below:
					Weighted
					Average			Total
		Number of			Issuance Date			Issuance Date
		Shares			Fair Value			Fair Value
Non-vested, December 31, 2014			-		$	-		$	-
Granted			312,795			0.27			85,128
Vested			-312,795			-0.27			-85,128
Forfeited			-			-			-
Non-vested, March 31, 2015			-		$	-		$	-

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 8 - Subsequent Events
	Common Stock and Warrant Offerings
	Subsequent to March 31, 2015, the Company issued an aggregate of 700,000 shares of common stock at prices ranging from $0.25 to $0.30 per share to investors for gross proceeds of $200,000. In connection with the purchases, the Company issued five-year warrants to purchase an aggregate of 175,000 shares of common stock at an exercise price of $0.75 per share of common stock.
	Stock-Based Compensation
	Subsequent to March 31, 2015, the Company issued an aggregate of 114,616 shares of common stock and five-year warrants to purchase an aggregate of 600,000 shares of common stock at exercise prices ranging from $0.38 to $0.60 per share to satisfy certain consulting and other obligations.
	Board of Directors
	On April 6, 2015, the Company elected a new director to replace a director who had previously resigned. Concurrent with the election, the Company granted a ten-year option to purchase 300,000 shares of common stock at an exercise price of $0.40 per share, pursuant to the Plan. The shares vest ratably over three years on the grant date anniversaries.
	Notes Payable
	On May 8, 2015, the Company issued a six-month convertible note with a principal amount of $100,000 which bears interest at a rate of 10% per annum payable upon maturity. The convertible note is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to at the greater of (a) 65% of the fair value of the Company’s stock or (b) $0.15 per share. In connection with the financing, a five-year warrant to purchase 126,923 shares of common stock at an exercise price of $0.50 per share was issued to the lender.
	On May 11, 2015, Cayman and the Bermuda Lender agreed to extend the maturity date of a note with a principal balance of $410,938 from May 7, 2015 to June 30, 2015 (the “New Maturity Date”). The Bermuda Lender waived any and all defaults under the note, including with respect to the failure by the Company to pay to the Bermuda Lender pursuant to the note the aggregate amount of $316,297 (the “Unpaid Amount”) received by the Company from its research and development agreements (see Note 3 – Summary of Significant Accounting Policies – Revenue Recognition – Research and Development Agreements). The Unpaid Amount shall be payable on the New Maturity Date together with all other amounts then payable pursuant to the note.
	On May 11, 2015, 2015, pursuant to the provisions of a convertible note with a principal balance of $75,000, the Company elected to convert the initial $25,000 of the principal, together with accrued interest of $1,205, into 118,043 shares of common stock at a conversion price of $0.22 per share.
	On May 14, 2015, the Company and a certain lender agreed to exchange a note payable with a principal balance of $282,873, along with accrued and unpaid interest of $25,296, for 1,027,231 shares of common stock and an immediately vested, five-year warrant to purchase 256,808 shares of common stock at an exercise price of $0.75 per share.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s equity securities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations and Credit Risk	Concentrations and Credit Risk
	As of March 31, 2015, 76% of the face value of the Company’s outstanding notes payable were sourced from a single entity (the “Bermuda Lender”). As of the date of filing, the maturity date associated with these notes was June 30, 2015. See Note 5 – Notes Payable and Note 8 – Subsequent Events – Note Payable for additional discussion of the Bermuda Lender.
	Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three months ended March 31, 2015. See Revenue Recognition – Research and Development Agreements below.
Revenue Recognition	Revenue Recognition
	Research and Development Agreements
	The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables.
	During the three months ended March 31, 2015, in connection with a March 19, 2014 research and development agreement with a Japanese pharmaceutical company, the Company received $50,000 upon achievement of a specified deliverable (milestone method). Through March 31, 2015, $200,000 had been received under the agreement and recognized as revenue. On February 11, 2015, the term of the agreement was extended by three months to June 19, 2015.
	During the three months ended March 31, 2015, in connection with a March 24, 2014 research and development agreement with a U.S. pharmaceutical company, the Company received the third and fourth of four quarterly payments in the aggregate amount of $177,234. Through March 31, 2015, $605,359 had been received and $210,882 was recorded as deferred revenues on the condensed consolidated balance sheet.
	During the three months ended March 31, 2015, the Company recognized revenue related to research and development agreements of $180,702. The Company did not recognize any revenue related to research and development agreements during the three months ended March 31, 2014.
	Other
	The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured.
	For the three months ended March 31, 2015 and 2014, the Company recognized revenue related to sales of Stem Pearls® skincare products of $200 and $375, respectively. In connection with its January 27, 2012 sublicense agreement with a stem cell treatment company, for the three months ended March 31, 2015 and 2014, the Company recognized royalty revenue of $4,000 and $0, respectively.
Net Loss Per Common Share	Net Loss Per Common Share
	Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes.
	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		March 31,
		2015		2014
	Options		16,184,000		7,783,000
	Warrants		9,099,516		5,325,751
	Convertible instruments		678,806		1,519,015
	Total potentially dilutive shares		25,962,322		14,627,766
Stock-Based Compensation	Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported by the OTCQB. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
Subsequent Events	Subsequent Events
	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:
		March 31,
		2015		2014
	Options		16,184,000		7,783,000
	Warrants		9,099,516		5,325,751
	Convertible instruments		678,806		1,519,015
	Total potentially dilutive shares		25,962,322		14,627,766

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following:
		March 31,		December 31,
		2015		2014
		(unaudited)
	Credit card payable	$	3,971	$	4,739
	Accrued payroll and payroll taxes		777,757		679,277
	Accrued purchases of property and equipment		74,587		174,801
	Accrued research and development expenses		316,175		292,395
	Accrued general and administrative expenses		679,069		315,294
	Deferred rent		33,000		-
	Total	$	1,884,559	$	1,466,506

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Notes Payable [Abstract]
Notes Payable	A summary of the notes payable activity during the three months ended March 31, 2015 is presented below:
			Bermuda		Convertible			Other		Debt
			Lender		Notes			Notes		Discount		Total
	Outstanding, December 31, 2014		$	4,410,937	$	175,000		$	1,265,559	$	-113,257	$	5,738,239
	Issuance			-		30,000			-		-		30,000
	Conversion to equity			-		-50,000			-		-		-50,000
	Recognition of debt discount			-		-			-		-16,590		-16,590
	Amortization of debt discount			-		-			-		69,515		69,515
	Outstanding, March 31, 2015		$	4,410,937	$	155,000	[1]	$	1,265,559	$	-60,332	$	5,771,164
		[1]	As of March 31, 2015, convertible notes with an aggregate principal balance of $155,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.

Stockholders_Deficiency_Tables

Stockholders' Deficiency (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Black-Scholes Option Pricing Model to Warrants Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to warrants granted/issued, the Company used the following assumptions:
			For The Three Months Ended
			March 31,
			2015			2014
	Risk free interest rate			1.22% - 1.61	%		0.39% - 2.20	%
	Expected term (years)			5			1.96 - 5.00
	Expected volatility			122	%		121	%
	Expected dividends			0	%		0	%
Summary of Warrant Activity	A summary of the warrant activity during the three months ended March 31, 2015 is presented below:
									Weighted
						Weighted			Average
						Average			Remaining			Aggregate
			Number of			Exercise			Life			Intrinsic
			Warrants			Price			In Years			Value
	Outstanding, December 31, 2014			8,248,683		$	0.9
	Granted			850,833			0.68
	Exercised			-			-
	Forfeited			-			-
	Outstanding, March 31, 2015			9,099,516		$	0.88			3.1		$	-
	Exercisable, March 31, 2015			8,399,516		$	0.83			3.2		$	-
Information Related to Stock Warrants	The following table presents information related to stock warrants at March 31, 2015:
	Warrants Outstanding							Warrants Exercisable
								Weighted
						Outstanding		Average			Exercisable
	Exercise				Number of			Remaining Life			Number of
	Price				Warrants			In Years			Warrants
	$	0.3				650,000			4.2			650,000
		0.4				250,000			4.7			250,000
		0.5				677,100			4.7			677,100
		0.53				380,000			3.1			380,000
		0.58				50,000			4.5			50,000
		0.75				4,669,222			2.9			4,669,222
		0.94				50,000			4.5			50,000
		1				550,000			4.2			550,000
		1.5				862,800			2.2			862,800
		1.75				20,000			2			20,000
		2				123,530			3.6			123,530
		2.5				20,000			2.3			20,000
		3				36,864			3.1			36,864
		4				60,000			2.5			60,000
		Variable	[1]			700,000			-			-
						9,099,516			3.2			8,399,516
		[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur as of March 31, 2015.
Black-Scholes Option Pricing Model to Stock Options Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:
			For the Three Months Ended
			March 31,
			2015			2014
	Risk free interest rate			1.33% - 1.64	%		1.5	%
	Expected term (years)			5.00 - 6.00			5.00 - 5.50
	Expected volatility			122	%		121	%
	Expected dividends			0	%		0	%
Stock option expense	The following table presents information related to stock option expense:
												Weighted
												Average
			For the Three Months Ended						Unrecognized at			Amortization
			March 31,						March 31,			Period
			2015			2014			2015			(Years)
	Consulting		$	96,803		$	100,613		$	585,273			2.3
	Research and development			128,432			121,390			755,231	[1]		2.4
	General and administrative			69,285			83,699			862,726			2.4
			$	294,520		$	305,702		$	2,203,230			2.4
		[1]	Includes $331,341 of expense that is subject to non-employee mark-to-market adjustments.
Summary of Option Activity	A summary of the option activity during the three months ended March 31, 2015 is presented below:
									Weighted
						Weighted			Average
						Average			Remaining			Aggregate
			Number of			Exercise			Life			Intrinsic
			Options			Price			In Years			Value
	Outstanding, December 31, 2014			15,584,000		$	0.61
	Granted			600,000			0.46
	Exercised			-			-
	Forfeited			-			-
	Outstanding, March 31, 2015			16,184,000		$	0.6			8.3		$	587,850
	Exercisable, March 31, 2015			7,196,502		$	0.88			7.5		$	28,850
Information Related to Stock Options	The following table presents information related to stock options at March 31, 2015:
	Options Outstanding						Options Exercisable
							Weighted
				Outstanding			Average			Exercisable
	Exercise			Number of			Remaining Life			Number of
	Price			Options			In Years			Options
	$	0.285			900,000			9.2			200,000
		0.32			500,000			-			-
		0.33			6,125,000			4.5			75,000
		0.34			250,000			-			-
		0.39			60,000			4.2			60,000
		0.46			500,000			-			-
		0.47			100,000			4.8			87,500
		0.5			345,000			4.6			345,000
		0.53			40,000			8.9			40,000
		0.6			980,000			8.5			980,000
		0.65			2,675,000			8.6			1,850,002
		1			131,000			7.7			131,000
		1.05			2,270,000			6.9			2,270,000
		1.1			5,000			2.2			5,000
		1.2			10,000			1.2			10,000
		1.25			43,000			1.6			43,000
		1.4			350,000			4.3			200,000
		1.5			900,000			7.7			900,000
					16,184,000			7.5			7,196,502
Common Stock Award Expense	The following table presents information related to compensatory common stock expense and does not include 18,847 shares valued at $8,481 which were issued in satisfaction of accrued professional services:
			For the Three Months Ended						Unrecognized at
			March 31,						March 31,
			2015			2014			2015
	Consulting		$	67,800		$	10,000		$	-
	Research and development			8,847			4,071			-
			$	76,647		$	14,071		$	-
Summary of Common Stock Award Activity	A summary of compensatory common stock issuances activity during the three months ended March 31, 2015 is presented below:
						Weighted
						Average			Total
			Number of			Issuance Date			Issuance Date
			Shares			Fair Value			Fair Value
	Non-vested, December 31, 2014			-		$	-		$	-
	Granted			312,795			0.27			85,128
	Vested			-312,795			-0.27			-85,128
	Forfeited			-			-			-
	Non-vested, March 31, 2015			-		$	-		$	-

Going_Concern_and_Managements_1

Going Concern and Management's Plans - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Working capital deficiency	$8,741,867
Stockholders deficiency	-7,395,292		-6,888,393
Net loss	-1,760,121	-1,669,676
Subsequent Event
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount raised through equity financing	200,000
Proceeds From Debt Financing	100,000
Subsequent Event | Notes Payable, Accrued Interest Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	26,501
Subsequent Event | Notes Payable, Principal Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity	$307,873

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Debt instrument outstanding face amount percentage	76.00%
Deferred Revenue, Current	$210,882		$164,349
Revenues	184,902	375
Research and Development Agreements One Year
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Payment Terms	the Company received $50,000 upon achievement of a specified deliverable (milestone method). Through March 31, 2015, $200,000 had been received under the agreement and recognized as revenue.
Research and Development Agreements Two Year
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Payment Terms	payments in the aggregate amount of $177,234. Through March 31, 2015, $605,359 had been received and $210,882 was recorded as deferred revenues on the condensed consolidated balance sheet.
Deferred Revenue, Current	210,882
Research and development agreements
Summary Of Significant Accounting Policies [Line Items]
Revenues	180,702
Stem Pearls Skincare Products
Summary Of Significant Accounting Policies [Line Items]
Revenue, Net, Total	200	375
Royalty Revenue	$4,000	$0

Calculation_of_Weighted_Averag

Calculation of Weighted Average Dilutive Common Shares (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	25,962,322	14,627,766
Options
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	16,184,000	7,783,000
Warrants
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	9,099,516	5,325,751
Convertible instruments
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	678,806	1,519,015

Recovered_Sheet1

Accrued Expenses And Other Current Liabilities - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer	$125,070	$0
Repayment of advances from officer	60,055	24,990
Liability to officer	$65,015

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accrued Expenses and Other Current Liabilities [Line Items]
Credit card payable	$3,971	$4,739
Accrued payroll and payroll taxes	777,757	679,277
Accrued purchases of property and equipment	74,587	174,801
Accrued research and development expenses	316,175	292,395
Accrued general and administrative expenses	679,069	315,294
Deferred rent	33,000	0
Total	$1,884,559	$1,466,506

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Debt Instrument [Line Items]
Debt Instrument, Convertible, Beneficial Conversion Feature	$10,690	$0
Convertible Notes
Debt Instrument [Line Items]
Aggregate principal amount	155,000
Rate of interest	12.00%
Debt instrument, face amount	50,000
Debt Instrument, Increase, Accrued Interest	5,984
Debt Instrument, Convertible, Conversion Price	$0.10
Debt Instrument Percentage For Fair Value	55.00%
Proceeds from Convertible Debt	30,000
Sale of Stock, Number of Shares Issued in Transaction	222,245
Sale of Stock, Price Per Share	$0.25
Bermuda Lender
Debt Instrument [Line Items]
Aggregate principal amount	$83,333

Notes_Payable_Detail

Notes Payable (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
Debt Instrument [Line Items]
Balance	$5,738,239
Issuances	30,000
Conversions to equity	-50,000
Recognition of debt discount	-16,590
Amortization of debt discount	69,515		98,505
Balance	5,771,164
Debt Discount
Debt Instrument [Line Items]
Balance	-113,257
Issuances	0
Conversions to equity	0
Recognition of debt discount	-16,590
Amortization of debt discount	69,515
Balance	-60,332
Bermuda Lender
Debt Instrument [Line Items]
Balance	4,410,937
Issuances	0
Conversions to equity	0
Recognition of debt discount	0
Amortization of debt discount	0
Balance	4,410,937
Convertible Notes Payable
Debt Instrument [Line Items]
Balance	175,000
Issuances	30,000
Conversions to equity	-50,000
Recognition of debt discount	0
Amortization of debt discount	0
Balance	155,000	[1]
Notes Payable, Other Payables
Debt Instrument [Line Items]
Balance	1,265,559
Issuances	0
Conversions to equity	0
Recognition of debt discount	0
Amortization of debt discount	0
Balance	$1,265,559
[1]	As of March 31, 2015, convertible notes with an aggregate principal balance of $155,000 were convertible at the election of the Company. Of such convertible notes, notes with an aggregate principal balance of $83,333 are also convertible, under certain circumstances, at the election of the holder pursuant to the terms of the notes.

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended
	Nov. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 09, 2015	Apr. 06, 2015	Feb. 09, 2015
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted		600,000
Common stock exercise price		$0.46
Rent Expense		$35,000	$11,000
Loss Contingency, Allegations	The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009.
Chief Executive Officer
Commitments and Contingencies Disclosure [Line Items]
Salaries, Wages and Officers Compensation, Total				400,000
Deferred Compensation Arrangement with Individual, Description				The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Companys Compensation Committee, are satisfied.
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount				100,000
Board of Directors | Subsequent Event
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted					300,000
Common stock exercise price					$0.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					3 years
Division President
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted						500,000
Common stock exercise price						$0.46
Severance Costs						150,000
Share Based Compensation Arrangement By Share Based Payment Award Options Grant Intrinsic Value						200,400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term						10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						3 years
Chief Executive Officer Employment Agreements
Commitments and Contingencies Disclosure [Line Items]
Severance Costs				125,000
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount				$300,000

Stockholders_Deficiency_Additi

Stockholders' Deficiency - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jan. 23, 2015	Jan. 01, 2015	Dec. 31, 2014	Dec. 19, 2014
Stockholders Equity Note Disclosure [Line Items]
Sales of common stock and warrants for cash	$801,000	$545,000
Weighted average estimated fair value of stock warrants granted, per share	$0.40	$0.23
Stock-based compensation expense	76,647	14,071
Share granted vested			12,500
Stock-based compensation, stock option granted	600,000
Stock-based compensation, stock options granted, exercise price	$0.46
Common stock, Authorized	200,000,000			200,000,000	200,000,000	100,000,000
Preferred stock, Authorized	5,000,000			5,000,000	5,000,000	1,000,000
Exercise Price Dollor One Point Five Zero
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted	700,000
Share based compensation shares authorized under stock option plans exercise price	$1.50
First Anniversary Of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested			75,000
Second Anniversary of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested			12,500
Employees, Directors and an Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted			100,000
Stock-based compensation, stock options granted, exercise price			$0.47
Consultant
Stockholders Equity Note Disclosure [Line Items]
Stock Issued During Period, Shares, Issued for Services	312,795
Stock Issued During Period, Value, Issued for Services	85,128
Professional Services
Stockholders Equity Note Disclosure [Line Items]
Stock Issued During Period, Shares, Issued for Services	18,847
Stock Issued During Period, Value, Issued for Services	8,481
Warrants
Stockholders Equity Note Disclosure [Line Items]
Weighted average estimated fair value of stock warrants granted, per share	$0.16	$0.22
Stock-based compensation expense	0	53,726
Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense	294,520	305,702
Non Employee Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense	331,341
Employee Awards
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, grant date fair value			39,200
Common Stock
Stockholders Equity Note Disclosure [Line Items]
Stock issued (in shares)	2,703,333
Sales of common stock and warrants for cash	801,000
Warrants to purchase common stock	850,833
Warrants aggregate grant date fair value	$138,383
Minimum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Shares issued, per share	$0.25
Warrants exercise price	$0.40
Estimated Forfeitures Related To Option Grants Annual Rate	0.00%	0.00%
Maximum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Shares issued, per share	$0.30
Warrants exercise price	$0.75
Estimated Forfeitures Related To Option Grants Annual Rate	5.00%	5.00%

BlackScholes_Option_Pricing_Mo

Black-Scholes Option Pricing Model to Warrant Granted, Weighted Average Assumptions (Detail) (Warrants)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years
Expected volatility	122.00%	121.00%
Expected dividends	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.22%	0.39%
Expected term (years)		1 year 11 months 16 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.61%	2.20%
Expected term (years)		5 years

Summary_of_Warrant_Activity_De

Summary of Warrant Activity (Detail) (Warrants, USD $)	3 Months Ended
	Mar. 31, 2015
Warrants
Number of Warrants
Beginning Balance	8,248,683
Granted	850,833
Exercised	0
Forfeited	0
Ending Balance	9,099,516
Exercisable	8,399,516
Weighted Average Exercise Price
Beginning Balance	$0.90
Granted	$0.68
Exercised	$0
Forfeited	$0
Ending Balance	$0.88
Exercisable	$0.83
Weighted Average Remaining Life In Years
Outstanding	3 years 1 month 6 days
Exercisable	3 years 2 months 12 days
Aggregate Intrinsic Value
Outstanding	$0
Exercisable	$0

Summarized_Information_Related

Summarized Information Related to Stock Warrants (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	9,099,516
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	8,399,516
Exercise Price 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.3
Warrants Outstanding, Number of Warrants	650,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	650,000
Exercise Price 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.4
Warrants Outstanding, Number of Warrants	250,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	250,000
Exercise Price 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.5
Warrants Outstanding, Number of Warrants	677,100
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	677,100
Exercise Price 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.53
Warrants Outstanding, Number of Warrants	380,000
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 1 month 6 days
Warrants Exercisable, Exercisable Number of Warrants	380,000
Exercise Price 5
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.58
Warrants Outstanding, Number of Warrants	50,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 6 months
Warrants Exercisable, Exercisable Number of Warrants	50,000
Exercise Price 6
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.75
Warrants Outstanding, Number of Warrants	4,669,222
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants	4,669,222
Exercise Price 7
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	0.94
Warrants Outstanding, Number of Warrants	50,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 6 months
Warrants Exercisable, Exercisable Number of Warrants	50,000
Exercise Price 8
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	1
Warrants Outstanding, Number of Warrants	550,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	550,000
Exercise Price 9
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	1.5
Warrants Outstanding, Number of Warrants	862,800
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	862,800
Exercise Price 10
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	1.75
Warrants Outstanding, Number of Warrants	20,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years
Warrants Exercisable, Exercisable Number of Warrants	20,000
Exercise Price 11
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	2
Warrants Outstanding, Number of Warrants	123,530
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants	123,530
Exercise Price 12
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	2.5
Warrants Outstanding, Number of Warrants	20,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	20,000
Exercise Price 13
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	3
Warrants Outstanding, Number of Warrants	36,864
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 1 month 6 days
Warrants Exercisable, Exercisable Number of Warrants	36,864
Exercise Price 14
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	4
Warrants Outstanding, Number of Warrants	60,000
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 6 months
Warrants Exercisable, Exercisable Number of Warrants	60,000
Exercise Price 15
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, Exercise Price Description	Variable	[1]
Warrants Outstanding, Number of Warrants	700,000
Warrants Exercisable, Weighted Average Remaining Life In Years	0 years
Warrants Exercisable, Exercisable Number of Warrants	0
[1]	Warrants to purchase 700,000 shares of common stock have an exercise price which is the greater of $1.50 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur as of March 31, 2015.

BlackScholes_Option_Pricing_Mo1

Black-Scholes Option Pricing Model to Stock Option Granted, Weighted Average Assumptions (Detail) (Stock Options)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.50%
Expected volatility	122.00%	121.00%
Expected dividends	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.33%
Expected term (years)	5 years	5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.64%
Expected term (years)	6 years	5 years 6 months

Information_Related_to_Stock_O

Information Related to Stock Option Expense (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$76,647		$14,071
Unrecognized expense	0
Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	294,520		305,702
Unrecognized expense	2,203,230
Weighted Average Amortization Period (Years)	2 years 4 months 24 days
Consulting | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	96,803		100,613
Unrecognized expense	585,273
Weighted Average Amortization Period (Years)	2 years 3 months 18 days
Research and development | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	128,432		121,390
Unrecognized expense	755,231	[1]
Weighted Average Amortization Period (Years)	2 years 4 months 24 days
General and administrative | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	69,285		83,699
Unrecognized expense	$862,726
Weighted Average Amortization Period (Years)	2 years 4 months 24 days
[1]	Includes $331,341 of expense that is subject to non-employee mark-to-market adjustments.

Summary_of_Stock_Option_Activi

Summary of Stock Option Activity (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Number of Options
Outstanding	15,584,000
Granted	600,000
Exercised	0
Forfeited	0
Outstanding	16,184,000
Exercisable	7,196,502
Weighted Average Exercise Price
Outstanding	$0.61
Granted	$0.46
Exercised	$0
Forfeited	$0
Outstanding	$0.60
Exercisable	$0.88
Weighted Average Remaining Life In Years
Outstanding	8 years 3 months 18 days
Exercisable	7 years 6 months
Intrinsic Value
Outstanding	$587,850
Exercisable	$28,850

Information_Related_to_Stock_O1

Information Related to Stock Options (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	16,184,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 6 months
Options Exercisable, Exercisable Number of Options	7,196,502
Exercise Price 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.285
Options Outstanding, Number of Options	900,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	200,000
Exercise Price 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.32
Options Outstanding, Number of Options	500,000
Options Exercisable, Weighted Average Remaining Life In Years	0 years
Options Exercisable, Exercisable Number of Options	0
Exercise Price 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.33
Options Outstanding, Number of Options	6,125,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 6 months
Options Exercisable, Exercisable Number of Options	75,000
Exercise Price 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.34
Options Outstanding, Number of Options	250,000
Options Exercisable, Weighted Average Remaining Life In Years	0 years
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.39
Options Outstanding, Number of Options	60,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	60,000
Exercise Price 6
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.46
Options Outstanding, Number of Options	500,000
Options Exercisable, Weighted Average Remaining Life In Years	0 years
Options Exercisable, Exercisable Number of Options	0
Exercise Price 7
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.47
Options Outstanding, Number of Options	100,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	87,500
Exercise Price 8
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.5
Options Outstanding, Number of Options	345,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	345,000
Exercise Price 9
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.53
Options Outstanding, Number of Options	40,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	40,000
Exercise price 10
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.6
Options Outstanding, Number of Options	980,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 6 months
Options Exercisable, Exercisable Number of Options	980,000
Exercise Price 11
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.65
Options Outstanding, Number of Options	2,675,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	1,850,002
Exercise Price 12
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1
Options Outstanding, Number of Options	131,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	131,000
Exercise Price 13
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.05
Options Outstanding, Number of Options	2,270,000
Options Exercisable, Weighted Average Remaining Life In Years	6 years 10 months 24 days
Options Exercisable, Exercisable Number of Options	2,270,000
Exercise Price 14
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.1
Options Outstanding, Number of Options	5,000
Options Exercisable, Weighted Average Remaining Life In Years	2 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	5,000
Exercise Price 15
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.2
Options Outstanding, Number of Options	10,000
Options Exercisable, Weighted Average Remaining Life In Years	1 year 2 months 12 days
Options Exercisable, Exercisable Number of Options	10,000
Exercise price 16
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.25
Options Outstanding, Number of Options	43,000
Options Exercisable, Weighted Average Remaining Life In Years	1 year 7 months 6 days
Options Exercisable, Exercisable Number of Options	43,000
Exercise Price 17
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.4
Options Outstanding, Number of Options	350,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	200,000
Exercise Price 18
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	1.5
Options Outstanding, Number of Options	900,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	900,000

Information_Related_to_Common_

Information Related to Common Stock Award Expense (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$76,647	$14,071
Unrecognized expense	0
Consulting | Common Stock Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	67,800	10,000
Unrecognized expense	0
Research and development | Common Stock Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	8,847	4,071
Unrecognized expense	$0

Summary_of_Common_Stock_Award_

Summary of Common Stock Award Activity (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value, Granted	$0.40	$0.23
Common Stock Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	0
Number of Shares, Granted	312,795
Number of Shares, Vested	-312,795
Number of Shares, Forfeited	0
Number of Shares, Ending Balance	0
Weighted Average Grant Date Fair Value, Beginning Balance	$0
Weighted Average Grant Date Fair Value, Granted	$0.27
Weighted Average Grant Date Fair Value, Vested	($0.27)
Weighted Average Grant Date Fair Value, Forfeited	$0
Weighted Average Grant Date Fair Value, Ending Balance	$0
Total Grant Date Fair Value, Beginning Balance	$0
Total Grant Date Fair Value, Granted	85,128
Total Grant Date Fair Value, Vested	-85,128
Total Grant Date Fair Value, Forfeited	0
Total Grant Date Fair Value, Ending Balance	$0

Subsequent_Events_Additional_I

Subsequent Events- Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended
	Mar. 31, 2015	14-May-15	11-May-15	Apr. 06, 2015	8-May-15
Subsequent Event [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	600,000
Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price	$0.46
Subsequent Event | Lender
Subsequent Event [Line Items]
Class of Warrant or Right, Outstanding		256,808
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.75
Debt Instrument Carrying Amount		$282,873
Debt Conversion Original Debt Accrued Interest Amount		25,296
Debt Conversion, Converted Instrument, Shares Issued		1,027,231
Warrants Exercisable Term		5 years
Subsequent Event | Cayman and the Bermuda Lender
Subsequent Event [Line Items]
Debt Instrument Carrying Amount			410,938
Debt Instrument, Maturity Date			30-Jun-15
Debt Instrument Unpaid Principle Balances, Amount			316,297
Subsequent Event | Board of Directors Chairman
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross				300,000
Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price				$0.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term				10 years
Subsequent Event | Six-Month Convertible Note
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Effective Percentage					10.00%
Debt Instrument, Convertible, Conversion Price			$0.22
Class of Warrant or Right, Outstanding					126,923
Class of Warrant or Right, Exercise Price of Warrants or Rights					$0.50
Debt Instrument Carrying Amount			75,000		100,000
Debt Instrument, Convertible, Terms of Conversion Feature					The convertible note is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to at the greater of (a) 65% of the fair value of the Company’s stock or (b) $0.15 per share.
Debt Conversion, Original Debt, Amount			25,000
Debt Conversion Original Debt Accrued Interest Amount			1,205
Debt Conversion, Converted Instrument, Shares Issued			118,043
Warrants Exercisable Term					5 years
Subsequent Event | Investor
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	700,000
Stock Issued During Period, Value, New Issues	$200,000
Class of Warrant or Right, Outstanding	175,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.75
Subsequent Event | Investor | Maximum
Subsequent Event [Line Items]
Sale of Stock, Price Per Share	$0.30
Subsequent Event | Investor | Minimum
Subsequent Event [Line Items]
Sale of Stock, Price Per Share	$0.25
Subsequent Event | Consultants and Others
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services	114,616
Class of Warrant or Right, Outstanding	600,000
Warrants Exercisable Term	5 years
Subsequent Event | Consultants and Others | Maximum
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.60
Subsequent Event | Consultants and Others | Minimum
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.38